Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Busulfan, Cyclophosphamide, and Thymoglobulin Conditioning for Allo-HSCT
NCT00611351Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Jun 2005
- Primary completion
- Feb 2008
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, cyclophosphamide, antithymocyte globulin rabbit in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), Chronic Myeloid Leukemia (CML), multiple myeloma (MM), myelodysplastic syndrome (MDS), sponsored by University of Nebraska. Started Jun 2005; status: completed.
02
Drugs
busulfancyclophosphamideantithymocyte globulin rabbit
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)Chronic Myeloid Leukemia (CML)multiple myeloma (MM)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00611351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00611351.